Paid Clinical Trials Knoxville
Discover 224 paid clinical trials in Knoxville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Sponsor:
Gilead Sciences
Location:
Code:
NCT03547973
Conditions
Metastatic Urothelial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan-hziy
Pembrolizumab
Cisplatin
Avelumab
Zimberelimab
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor:
Sanofi
Location:
Code:
NCT06141473
Conditions
Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Frexalimab
Teriflunomide
Placebo infusion
Placebo tablet
MRI contrast-enhancing agents
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Sponsor:
AbbVie
Location:
Code:
NCT05889182
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Placebo
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT04811560
Conditions
Acute Leukemias
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Bleximenib
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT05040360
Conditions
Metastatic Malignant Neoplasm in the Liver
Pancreatic Neuroendocrine Tumor
Stage I Pancreatic Neuroendocrine Tumor AJCC v8
Stage II Pancreatic Neuroendocrine Tumor AJCC v8
Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Capecitabine
Temozolomide
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06077760
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
V940
Pembrolizumab
Placebo
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT05636176
Conditions
Heart Failure
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ziltivekimab
Placebo
A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06074562
Conditions
Diabetic Peripheral Neuropathy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
LY3556050
Placebo
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Sponsor:
Replimune Inc.
Location:
Code:
NCT06264180
Conditions
Advanced Melanoma
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Vusolimogene Oderparepvec
Nivolumab
Nivolumab + Relatlimab
Pembrolizumab
Single-agent chemotherapy